- Home
- BNT vs BIIB Comparison
BNT vs BIIB Comparison
Compare BNT & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNT
- BIIB
- Stock Information
- Founded
- BNT 2020
- BIIB 1978
- Country
- BNT Bermuda
- BIIB United States
- Employees
- BNT N/A
- BIIB N/A
- Industry
- BNT
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- BNT
- BIIB Health Care
- Exchange
- BNT Nasdaq
- BIIB Nasdaq
- Market Cap
- BNT 14.1B
- BIIB 18.7B
- IPO Year
- BNT N/A
- BIIB 1991
- Fundamental
- Price
- BNT $45.57
- BIIB $154.38
- Analyst Decision
- BNT
- BIIB Buy
- Analyst Count
- BNT 0
- BIIB 24
- Target Price
- BNT N/A
- BIIB $174.62
- AVG Volume (30 Days)
- BNT 21.4K
- BIIB 1.6M
- Earning Date
- BNT 11-11-2025
- BIIB 10-30-2025
- Dividend Yield
- BNT 0.53%
- BIIB N/A
- EPS Growth
- BNT N/A
- BIIB N/A
- EPS
- BNT 1.85
- BIIB 10.97
- Revenue
- BNT $14,371,000,000.00
- BIIB $10,065,900,000.00
- Revenue This Year
- BNT N/A
- BIIB $2.97
- Revenue Next Year
- BNT N/A
- BIIB N/A
- P/E Ratio
- BNT $24.67
- BIIB $14.17
- Revenue Growth
- BNT 57.06
- BIIB 4.77
- 52 Week Low
- BNT $29.13
- BIIB $110.04
- 52 Week High
- BNT $49.44
- BIIB $176.95
- Technical
- Relative Strength Index (RSI)
- BNT 29.65
- BIIB 59.29
- Support Level
- BNT $44.93
- BIIB $148.90
- Resistance Level
- BNT $46.01
- BIIB $157.79
- Average True Range (ATR)
- BNT 0.88
- BIIB 4.78
- MACD
- BNT 0.71
- BIIB 0.43
- Stochastic Oscillator
- BNT 21.90
- BIIB 82.77
About BNT Brookfield Wealth Solutions Ltd.
Brookfield Wealth Solutions Ltd, formerly Brookfield Reinsurance Ltd operates a capital solutions business providing insurance and reinsurance services to individuals and institutions. Through its subsidiary, the company offers a broad range of insurance products and services, including life insurance and annuities, and personal and commercial property and casualty insurance. It is organized into three reporting segments: Direct Insurance, Reinsurance, and Pension Risk Transfer (PRT).
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.